ST. LOUIS & TOKYO–(BUSINESS WIRE)– #Alzheimers–C2N Diagnostics, LLC (C2N) and LSI Medience Corporation (LSIM) today announced a strategic partnership to pursue regulatory approval and commercialization of PrecivityAD2® in Japan, following the test’s recent U.S. FDA clearance1. The collaboration combines C2N’s expertise in high-resolution mass spectrometry and Alzheimer’s diagnostics with LSIM’s established clinical laboratory, regulatory and commercial capabilities in Japan. In the United States, Precivit
